Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Louis K. Chang"'
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 22, Iss , Pp 101046- (2021)
Purpose: To report a case of a hemi-retinal vein occlusion (HRVO) in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Observations: A 32-year-old healthy male presented with a paracentral scotoma, retinal hemorrhages, and
Externí odkaz:
https://doaj.org/article/4cfbed2d66e149578f266e683d6f3c7d
Autor:
Rahul N. Khurana, Louis K. Chang, Alok S. Bansal, James D. Palmer, Chengqing Wu, Mark R. Wieland
Publikováno v:
International Journal of Retina and Vitreous, Vol 5, Iss 1, Pp 1-7 (2019)
Abstract Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlu
Externí odkaz:
https://doaj.org/article/dd48c4d78a46477fbf7d52d70f90c84c
Autor:
Avnish Deobhakta, Louis K. Chang
Publikováno v:
International Journal of Inflammation, Vol 2013 (2013)
Retinal vein occlusion is a common, vision-threatening vascular disorder. The role of inflammation in the pathogenesis and clinical consequences of retinal vein occlusion is a topic of growing interest. It has long been recognized that systemic infla
Externí odkaz:
https://doaj.org/article/746578b3efec43dcbc1faec7621f0b0b
Autor:
Noy Ashkenazy, Nimesh A. Patel, Jayanth Sridhar, Nicolas A. Yannuzzi, Peter J. Belin, Richard Kaplan, Nikisha Kothari, Gabriel A. Benitez Bajandas, Radha P. Kohly, Roberto Roizenblatt, Alexander Pinhas, Rusdeep Mundae, Richard B. Rosen, Edwin H. Ryan, Allen Chiang, Louis K. Chang, Rahul N. Khurana, Avni P. Finn
Publikováno v:
Ophthalmology Retina. 6:520-530
Venous thromboembolic complications have been reported in association with coronavirus disease 2019 (COVID-19) infection. We raised awareness regarding a potential temporal association between COVID-19 infection and retinal vein occlusion (RVO).Multi
Autor:
Clement K. Chan, Maziar Lalezary, Prema Abraham, Michael Elman, Wesley Thomas Beaulieu, Steven G. Lin, Rahul N. Khurana, Alok S. Bansal, Mark R. Wieland, James D. Palmer, Louis K. Chang, Brandon J. Lujan, Glenn Yiu
Publikováno v:
Ophthalmology Retina. 6:484-494
Publikováno v:
Ophthalmology Retina. 4:760-766
Purpose To investigate whether time to peak best-corrected visual acuity (BCVA) was predictive of magnitude of BCVA changes at study end in patients with neovascular age-related macular degeneration (nAMD) who received ranibizumab and assess whether
Publikováno v:
Ophthalmology Retina. 4:13-18
Purpose To evaluate disease activity–free intervals of patients with neovascular age-related macular degeneration (nAMD) in the pHase III, double-masked, multicenter, randomized, Active treatment-controlled study of the efficacy and safety of 0.5 m
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 22, Iss, Pp 101046-(2021)
American Journal of Ophthalmology Case Reports
American Journal of Ophthalmology Case Reports
Purpose To report a case of a hemi-retinal vein occlusion (HRVO) in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Observations A 32-year-old healthy male presented with a paracentral scotoma, retinal hemorrhages, and di
Autor:
Mark R. Wieland, Chengqing Wu, James D. Palmer, Louis K. Chang, Alok S. Bansal, Rahul N. Khurana
Publikováno v:
International Journal of Retina and Vitreous, Vol 5, Iss 1, Pp 1-7 (2019)
International Journal of Retina and Vitreous
International Journal of Retina and Vitreous
Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CR
Publikováno v:
Ophthalmology. Retina. 4(1)
To evaluate disease activity-free intervals of patients with neovascular age-related macular degeneration (nAMD) in the pHase III, double-masked, multicenter, randomized, Active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0